and Kyowa Kirin’s anti-CCR4 antibody Poteligeo (mogamulizumab) – the last drug to be approved by the FDA for CTCL in 2018 – have been shown to drive the disease into remission. A phase 3 ...

Shanghai Pharmaceuticals Holding Co. Ltd. has identified C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, ...

Pembrolizumab demonstrated clinical activity in patients with mycosis fungoides (MF) and Sézary syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL), with nearly half of ...

This rapid response is a distinct advantage of HyBryte™ therapy, with many other therapies used in CTCL taking up to six to 12 months to generate a clinically meaningful treatment response.